Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Revenue (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Revenue for 16 consecutive years, with $20.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 6.27% to $20.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $87.4 million, a 10.6% decrease, with the full-year FY2024 number at $94.1 million, down 16.14% from a year prior.
  • Revenue was $20.6 million for Q3 2025 at Harvard Bioscience, up from $20.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $33.1 million in Q4 2021 to a low of $20.4 million in Q2 2025.
  • A 5-year average of $26.4 million and a median of $27.0 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: grew 25.27% in 2021, then dropped 19.69% in 2024.
  • Harvard Bioscience's Revenue stood at $33.1 million in 2021, then decreased by 14.0% to $28.4 million in 2022, then fell by 0.96% to $28.2 million in 2023, then fell by 12.78% to $24.6 million in 2024, then fell by 16.15% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Revenue are $20.6 million (Q3 2025), $20.4 million (Q2 2025), and $21.8 million (Q1 2025).